NASDAQ$TSHA
Taysha Gene Therapies Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported full-year financial results and provided a corporate update.
Taysha Gene Therapies reported its full-year 2020 financial results, highlighting significant progress in its pipeline initiatives, technology platforms, and manufacturing strategy. The company anticipates a transformational year in 2021 with upcoming clinical data and trial initiations.
- Completed one of the fastest seed to IPOs in biotech history.
- Advanced pipeline initiatives, next-generation technology platforms and manufacturing strategy.
- Expects to report first-in-human clinical data for TSHA-101 in GM2 gangliosidosis and initiating Phase 1/2 trials in CLN1 disease, Rett syndrome and SURF1-associated Leigh syndrome in 2021.
- Grown from a handful of employees at inception to approximately 80 as of the end of February.
Headline financials
Revenue & EPS history
Taysha Gene Therapies · Revenue · Quarterly
$0
Forward guidance
Taysha Gene Therapies anticipates several milestones in 2021, including clinical data reports, IND submissions, and trial initiations across its gene therapy programs. The company also plans to advance its technology platform and expand its manufacturing capabilities.
Tailwinds
- Report preliminary Phase 1/2 safety and biomarker data (Queen’s University trial) in the second half of 2021
- Submit an Investigational New Drug (IND) application in the U.S. in the second half of 2021
- Initiate Phase 1/2 clinical trial in the U.S. in the second half of 2021
- Report preliminary Phase 1/2 clinical data (Queen’s University trial) by year-end 2021
- Initiate a Phase 1/2 clinical trial in the second half of 2021 with commercial-grade GMP material
Headwinds
- Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties
- Risks regarding our business are described in detail in our Securities and Exchange Commission filings
- Such risks may be amplified by the impacts of the COVID-19 pandemic.
- The company had a net loss of $60.0 million for the year ended December 31, 2020
- Change in fair value of preferred stock tranche liability (17,030 )
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+10.9%
Avg return
Earnings day
+11.7%
Avg return
5 days after
+18.2%
Avg return
30 days after
52%
12 / 23 earnings
Positive
+195.0%
Q2 2023
Best reaction
-16.0%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -3.5% | -6.3% | — | |
| Q1 2026 | +0.6% | -1.6% | -20.9% | |
| Q3 2025 | -5.9% | -8.9% | +18.3% | |
| Q2 2025 | +5.4% | +6.5% | +17.4% | |
| Q1 2025 | +8.1% | +23.6% | +7.2% | |
| Q4 2024 | -4.7% | -4.7% | +13.5% | |
| Q3 2024 | -5.0% | -4.6% | -13.4% | |
| Q2 2024 | +9.1% | +7.7% | +11.0% | |
| Q1 2024 | +29.6% | +28.7% | +73.7% | |
| Q4 2023 | +39.0% | +52.6% | +13.1% | |
| Q3 2023 | +26.3% | +27.8% | +16.5% | |
| Q2 2023 | +195.0% | +159.8% | +312.7% | |
| Q1 2023 | -10.5% | -7.7% | +14.7% | |
| Q4 2022 | -6.5% | +14.8% | -3.9% | |
| Q3 2022 | -5.5% | +9.0% | +2.5% | |
| Q2 2022 | -16.0% | -16.4% | -29.9% | |
| Q1 2022 | -4.1% | -19.5% | -12.5% | |
| Q4 2021 | +3.1% | +8.5% | -40.5% | |
| Q3 2021 | +0.2% | -3.1% | -9.3% | |
| Q2 2021 | +0.7% | -2.6% | +20.1% | |
| Q1 2021 | -0.7% | +2.0% | +19.9% | |
| Q4 2020 | -7.2% | -0.2% | -19.9% | |
| Q3 2020 | +2.2% | +4.0% | +10.3% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro